Shape Therapeutics, Inc.

Roche is to collaborate with Ascidian Therapeutics to discover and develop novel RNA exon editing therapeutics targeting neurological diseases, in a deal that could be worth up to $1.8bn. The Bosto

Otsuka Pharmaceutical Co. Ltd. has teamed up Seattle, US-based biotech Shape Therapeutics, Inc. (ShapeTX) to further expand its R&D capabilities related to gene therapies for eye disorders. The up

Who: Roche Holding AG and Avista Therapeutics What: The two companies signed a partnership to use Avista’s intravitreal AAV platform technology to develop AAV capsids matching a profile defined by

Barbara Lueckel, Roche Holding AG ’s head of research technologies, said in an interview with Scrip that the primary change in dealmaking due to the ongoing turmoil in global financial markets is t